Rodolfo Hrosz has chosen to step down from his position as Managing Director of the company, effective April 30. He will be ...

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the ...

As per the company, the drug functions by blocking a protein called RANKL, which is responsible for breaking down bone tissue ...